Exam 1 Flashcards
precision medicine
tailoring disease prevention and treatment taking into account differences in indv genes, environments, and lifestyles
precision therapeutics
customizing medications to pts categorized by molecular + cellular biomarkers to improve treatment outcomes
pharmacogenetics
study of individual gene-drug interactions, usually involving 1 or 2 genes that have a dominant effect on a drug response (simple relationships)
Pharmacogenomics
study of genomic effects on drug response, often using high throughput data (sequencing, SNP chip, expression, etc) - COMPLEX interactions
What determines drug response
genetics
disease
environment
lifestyle
concomitant medications
Effects of genetic variation on medication therapy
varied drug absorption
varied metabolism rates
varied elimination rates
variations in receptors leading to variation in drug effect
Genome
organism’s entire genetic material found in cells, including genes and regulatory elements
Chromosome
Cellular structure containing genes (composed of DNA + proteins)
Gene
segment of DNA that contains info for making protein or RNA molecule
Nucleotide
building block of DNA/RNA including 1 base, 1 phosphate, and 1 sugar molecule
Allele
one of 2+ alternate forms of a gene containing specific inheritance characteristics
Genotype
genetic constitution
Phenotype
outward characteristic
Single Nucleotide Polymorphisms
Common genetic single nucleotide variants resulting from a single base pair change
Synonymous SNP
no change in amino acids, can alter mRNA stability
Non-synonymous SNP
nucleotide that alters amino acid sequence of protein
Missense SNP
change in 1 DNA base pair that results in substitution of one amino acid for another in the resulting protein
Nonsense SNP
results in insertion of stop codon
SNP nomenclature
C for coding DNA sequence (c. 67A>T)
P for protein sequence (p. tryp24cys)
normal/extensive metabolizer phenotype
normal function/decreased function alleles -> fully functional enzyme
intermediate metabolizer phenotype
combo of normal function and decreased function/no function alleles -> slightly decreased enzyme activity
poor metabolizer phenotype
combo of decreased function and no function alleles -> significantly decreased or absent enzyme activity
rapid metabolizer phenotype
combo of normal function and increased function alleles -> increased enzyme activity
ultra-rapid metabolizer phenotype
combo of increased function alleles or >2 normal function alleles -> very increased enzyme activity
CPIC
Clinical Pharmacogenetics Implementation Consortium that posts gene/drug clinical guidelines
CPIC level A/B
have evidence for prescribing action
CPIC levels C/D
Do not have adequate evidence for prescribing action
CPIC recommendation levels
Strong, moderate, optional, none
Which drugs does CPIC provide guidelines for
- drugs with a PharmGKB clinical annotation level of evidence 1a,1b,2a,2b
- drug with PharmGKB level/FDA drug label recommendations of actionable PGX genetic testing
PharmGKB
pharmacogenomics knowledge base - more scientific than clincial
What population is used to determine pgx recommendations in package inserts
a “ballpark estimate” of the population